Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2003, p. 9349-9360, Vol. 23, No. 24
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.24.9349-9360.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
4 Integrins from Adult Hematopoietic Cells Reveals Roles in Homeostasis, Regeneration, and Homing
Gregory V. Priestley, and Thalia Papayannopoulou*
Division of Hematology, University of Washington, Seattle, Washington 98195-7710
Received 24 June 2003/ Returned for modification 15 August 2003/ Accepted 18 September 2003
| ABSTRACT |
|---|
|
|
|---|
4
integrin deletion during adult hematopoiesis by generating a
conditional-knockout mouse model, and we show that
4
integrin-deficient hematopoietic progenitor cells accumulate in the
peripheral blood soon after interferon-induced gene deletion. Although
their numbers gradually stabilize at a lower level, progenitor cell
influx into the circulation continues at above-normal levels for more
than 50 weeks. Concomitantly, a progressive accumulation of progenitors
occurs within the spleen. In addition, the regeneration of erythroid
and myeloid progenitor cells is delayed during stress hematopoiesis
induced by phenylhydrazine or by 5-fluorouracil, suggesting impairment
in early progenitor expansion in the absence of
4 integrin.
Moreover, in transplantation studies, homing of
4-/- cells to the bone
marrow, but not to the spleen, is selectively impaired, and short-term
engraftment is critically delayed in the early weeks after
transplantation. Thus, conditional deletion of
4 integrin in
adult mice is accompanied by a novel hematopoietic phenotype during
both homeostasis and recovery from stress, a phenotype that is distinct
from the ones previously described in
4 integrin-null chimeras
and ß1 integrin-conditional
knockouts. | INTRODUCTION |
|---|
|
|
|---|
To uncover integrin functions in the process of
hematopoiesis, early studies used antibodies that not only defined
their expression patterns but also uncovered their function and
responses to stimuli in vitro and in vivo. These studies found that the
ß1 integrins are expressed by a wide variety of cell types,
whereas the ß2 integrins are found exclusively in hematopoietic
cells (56,
63). Expression of
ß1 and ß2 integrins is also differentiation dependent,
with mature cells exhibiting diminished or inactive expression of
4ß1 integrin
(41,
56,
63) in contrast to stem
and progenitor cells, which express
4 integrin in a
constitutively active state
(21,
38). Cells from different
stages of development also display differential patterns of integrin
expression. For example, fetal cells express more
2ß1
integrin than do adult cells, a factor which dictates functional
differences in their ability to adhere to collagen IV
(52). Similarly, yolk
sac-derived primitive erythroid cells display little
4 or
5 integrin expression in contrast to high levels expressed by
fetal liver (FL) erythroid and adult bone marrow (BM) cells
(40,
41). Perturbation of
4 integrin function in long-term BM cultures by an
anti-
4 integrin antibody blocked the in vitro development of
progenitors into mature erythroid, lymphoid, and myeloid cells
(36,
70). Similarly,
anti-
4 integrin antibodies injected into pregnant mice
resulted in inhibition in FL erythroid development, but with little
effect on lymphoid or myeloid development
(15). In vivo studies
have revealed additional roles for
4ß1 integrin and
its ligand, vascular cell adhesion molecule 1 (VCAM-1), in the homing
to and short-term engraftment in the BM
(42,
75). In vivo studies also
stressed the role of
4 integrin in influencing migration of
hematopoietic progenitors from the BM into circulation
(9,
23,
43,
62,
71).
Experiments in
mice deficient in ß1 or
4 integrins have provided
direct evidence of the involvement of integrins in hematopoiesis.
Deletion of either the
4 or ß1 integrin gene caused
embryonic lethality from nonhematological defects
(10,
58,
72); deletion of VCAM-1
resulted in a phenotype identical to that of the
4 integrin
knockout (13,
28). Early lethality
consequently precluded significant analysis of the roles of these
adhesion molecules in hematopoietic development, although yolk sac
hematopoiesis did remain intact in the
4 integrin knockout
(3). The transition from
4 integrin independence to dependence at the liver
colonization stage might explain the preservation of primitive
erythropoiesis in
4 knockout animals. Studies with chimeric
mice showed that
4 integrin-deficient hematopoiesis was
compromised in the FL and was extinguished shortly after birth
(3,
4). Although FL progenitor
cells differentiated normally in vitro, their terminal differentiation
in the FL and BM was impaired in the absence of
4 integrin,
resulting in decreased proliferation and differentiation. Furthermore,
ß1 integrin-deficient cells were not able to colonize the FL,
nor were they able to colonize the adult BM, spleen, or thymus of
chimeras (18). However,
in contrast to the significant defects in hematopoiesis in
4
chimeric mice and the migratory failure of ß1-null cells during
development, recent analysis of adult mice with conditional deletion of
ß1 integrin demonstrated no perturbations in myelopoiesis in
the absence of all ß1 integrins
(6). Moreover, it is
noteworthy that both of these genetic studies appear to diverge from
studies obtained in vivo with the use of
4 or ß1
antifunctional antibodies, although the interpretation of data with
monoclonal antibodies has been questioned because of unwanted side
effects either by steric hindrance of other interactions or by partial
activation of target cells and/or binding to irrelevant cells
(6).
Because of the
difficulties in assigning specific roles to
4 integrin in
hematopoiesis, especially between fetal and adult stages, we have
generated conditional-knockout mice with
4 integrin alleles
designed to be disrupted upon treatment of adult animals with
interferon. This approach not only bypasses the embryonic lethality
observed in
4 integrin knockouts but also causes a
cell-intrinsic deficiency that cannot be restored by a normal BM
microenvironment. By studying myelopoiesis before and after induction
of stress, a novel hemopoietic phenotype was unveiled in these mice
that has certain similarities to that of
4 integrin chimeras
but displays significant differences from both these mice and the
ß1 integrin-conditional knockouts. The present studies expand
our understanding of the role of
4 integrin in adult
hematopoiesis at both the cellular and molecular
levels.
| MATERIALS AND METHODS |
|---|
|
|
|---|
4 integrin knockout mice.
A 13.9-kb clone containing the
proximal end of the murine
4 integrin gene
(
4) was isolated from a 129S4/SvJaeSor-derived
genomic library (Stratagene, La Jolla, Calif.). The targeting vector
was constructed from a 5.95-kb XbaI/SphI
4 restriction fragment that included the promoter and
first two exons, a PGK-neo-p(A) cassette flanked by
loxP elements, inserted at a KpnI site in the
promoter, and an additional loxP, inserted at a
HindIII site distal to the second exon. The diphtheria toxin A
chain gene was added as a negative selection marker
(68). AK7 embryonic stem
(ES) cells were maintained on mitomycin C-inactivated SNL 76/7 feeder
cells in medium containing 500 U of leukemia inhibitory factor
(Gibco-BRL, New York, N.Y.) per ml. A total of 8 x
106 AK7 cells were electroporated at 240 V and 500
µF with 25 µg of linearized targeting vector by using a
GenePulser electroporator (Bio-Rad Laboratories, Hercules, Calif.); the
cells were then selected in 300 µg of G418. Clones with a
floxed (that is, flanked by loxP)
4 allele
(
4flox) resulting from homologous
recombination were identified by amplification reactions with primers
specific to the distal loxP and a region of intron II not
included in the targeting vector
(5'-TGAAGAGGAGTTTACCCAGC-3' and
5'-CACCCTTAGCTCATCATCATCG-3').
Candidate clones were analyzed by Southern blot analyses
using probes proximal and distal to the 5.95-kb
XbaI/SphI restriction fragment. Targeted clones with
a normal XY karyotype were injected into C57BL/6
blastocysts 3.5 days postcoitum and transferred into pseudopregnant
females. The resulting high percentage of male chimeras, identified by
the level of agouti coat color, were bred to C57BL/6 females. Offspring
were genotyped by tail tipping and polymerase chain reactions with
primers flanking the distal loxP sequence
(5'-GTCCACTGTTGGGCAAGTCC-3' and
5'-AAACTTGTCTCCTCTGCCGTC-3'),
which were carried out with an annealing temperature of
61°C. Animals heterozygous for the floxed
4
allele (
4flox) were crossed to generate
floxed homozygotes.
Animals and
treatment.
Mice were bred
and maintained under specific-pathogen-free conditions in University of
Washington facilities under a 12-hour light-dark cycle, and they were
provided with irradiated food and autoclaved water ad libitum. The
4flox/flox females were bred to
Mx.cre+ males
(27), and the progeny
were screened for the cre transgene by slot blot analysis.
Mx.cre+
4flox/+
mice were intercrossed, and the Mx.cre+
progeny were genotyped with respect to the
4 allele.
Six-to-eight-week-old gender-matched
Mx.cre+
4+/+and
Mx.cre+
4flox/flox
mice were used for all experiments. Cre recombinase was induced by
three intraperitoneal injections of 300 µg of poly(I)-poly(C)
(Sigma Chemical Company, St. Louis, Mo.) at 2-day intervals, and the
mice were then analyzed at least 14 days after the final
injection.
The capacity of
Mx.cre+
4+/+
and
Mx.cre+
4
/
leukocytes and progenitor cells to recover from cytotoxic stress was
assessed after intravenous injection of 150 mg of 5-fluorouracil (5FU)
per kg of body weight 3 weeks after poly(I)poly(C) treatment. Animals
were killed 4, 8, 12, or 16 days later, and the progenitor content was
assessed by using the assay for colony-forming cells (CFU-C) described
below. The capacity of
4+/+ and
4
/
mice to recover from
acute hemolysis was assessed after two daily intraperitoneal injections
of 60 mg of phenylhydrazine (PHZ; Sigma Chemical Company) per kg.
Reticulocyte and platelet numbers were determined in peripheral blood
(PB) samples obtained retro-orbitally 2, 4, 6, 8, and 10 days later
with an automated cell counter. In a separate cohort, mice were
euthanized 2 days after the last injection, and hematopoietic tissues
were analyzed for CFU-C content in methylcellulose and plasma clot
assays.
CFU-C assays. To quantitate committed progenitors of all lineages, CFU-C assays were performed using methylcellulose semisolid media (Stemgenix, Amherst, N.Y.) supplemented with an additional 50 ng of stem cell factor (Peprotech, Rocky Hill, N.J.) per ml. Next, 0.1 ml of lysed PB, 50,000 BM cells, and 500,000 spleen cells were plated on duplicate 35-mm culture dishes and then incubated at 37°C in a 5% CO2-95% air mixture in a humidified chamber for 7 days. Colonies generated by that time were counted by using a dissecting microscope, and all colony types (i.e., burst forming units-erythroid [BFU-e], CFU-granulocyte-macrophage [CFU-GM], and CFU-mixed [CFU-GEMM]) were pooled and reported as total CFU-C. CFU-erythroid (CFU-e) cells were assessed only in plasma clot cultures, as their evaluation in methylcellulose cultures is inaccurate. In plasma clots, BFU-e can also be concurrently evaluated. Plasma clots were prepared as described previously (44).
Fluorescence-activated
cell sorter (FACS) analysis.
Hematopoietic cells were analyzed on
a FACSCalibur (BD Immunocytometry Systems, San Jose, Calif.) by using
the CELLQuest program. Staining was performed by using antibodies
conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), or
allophycocyanin. The following BD Pharmingen (San Diego, Calif.)
antibodies were used for cell surface staining:
allophycocyanin-conjugated c-kit (2B8) and CD45 (30F-11);
PE-conjugated CD4 (RM4-5), B220 (RA3-6B2), Mac1 (M1/70), Ter119
(Ly-76),
2 integrin (HMa2),
5 integrin (MFR5),
6 integrin (GoH3), and CD11a (2D7); and FITC-conjugated CD3
(145-2C11), ß1 integrin (Ha2/5), and ß2 integrin
(c71/16). PE-conjugated anti-
4 integrin (PS/2) was from
Southern Biotechnology, Birmingham Ala. Irrelevant isotype-matched
antibodies were used as
controls.
Retroviral vectors and
transduction of BM cells.
Stable producer lines were generated
by infection of GpE86 packaging cells
(34) with viral
supernatants produced by transient transfection of BOSC23 cells with
plasmids encoding MSCViresGFP or MSCV-cre-iresGFP
(46). Following
infection, transduced GpE86 cells were purified on the basis of green
fluorescent protein (GFP) positivity.
Mx.cre+
4flox/flox
animals were injected intraperitoneally with 150 mg of 5FU per kg, and
BM cells were recovered 2 days later. These were incubated at a
concentration of 4 x 106 cells/ml for 48 h
in Iscoves modified Dulbecco medium with
10% fetal bovine serum (HyClone, Logan, Utah), 5% murine
interleukin 3 culture supplement (Collaborative Biomedical Products,
Bedford, Mass.), 50 ng of human interleukin 6 (Amgen, Thousand Oaks,
Calif.) per ml, and 50 ng of murine stem cell factor per ml. BM cells
were plated on irradiated monolayers of each producer line and
cocultured for 48 h prior to
analysis.
Homing assays and
transplantation studies.
In
homing assays, donor animals
(Mx.cre+
4+/+
or
Mx.cre+
4
/
)
were sacrificed, and single-cell suspensions of the BM were
prepared, counted, and used for transplantation at appropriate
concentrations. An aliquot was also plated in methylcellulose cultures
to quantify committed progenitor cells of various lineages present in
donor cells. In all homing experiments, 20 x 106 to
30 x 106 cells were injected through the tail vein
into mice subjected to 1,150-cGy whole-body irradiation with
137Cs. In certain experiments, donor cells were incubated
for 30 min at 4°C in the presence of low-endotoxin, azide-free
unconjugated antibody and then washed before intravenous infusion.
Twenty-four hours later, recipients of fresh or antibody-treated cells
were sacrificed under anesthesia, and the BM, spleen, and PB were
collected. Single-cell suspensions of BM and spleen were prepared and
cultured in duplicate to assess donor CFU-C recovery (CFU-GM, CFU-GEMM,
and BFU-e) in the recipient animals. The number of donor CFU-C
recovered after 24 h in BM, PB, or spleen was expressed as a
percentage of total CFU-C infused. For estimating total BM recovery,
the femur content was assumed to represent 6.7% of total BM
(5).
For evaluating
short-term engraftment, irradiated recipients were transplanted with
0.5 x 106, 1.0 x 106, or 5.0
x 106 donor cells
(
+/+ or
4-/-) and analyzed 2 weeks after
transplantation. Evaluation of total cell and total CFU-C content in
BM, spleen, and PB was done as
above.
Statistical analysis.
Results are expressed as the mean
± standard error of the mean. Data were analyzed using the
unpaired two-tailed Student's t test. P values
that were
0.05 were considered
significant.
| RESULTS |
|---|
|
|
|---|
4 integrin-knockout mice.
To study the roles of
4
integrin in adult hematopoiesis, we used conditional gene inactivation
by cre-loxP-mediated recombination to produce a
conditional
4 integrin-knockout mouse. A targeting vector was
constructed in which a neomycin-resistance cassette flanked by
loxP sequences was introduced into the promoter of the
4 integrin gene (
4), and an additional
loxP was inserted downstream of the second exon (Fig.
1A). This was designed so that the regulatory elements required for
expression and the start of the coding region would be deleted by Cre
recombinase expression to produce a null allele similar to
that reported previously
(72). The targeting
vector was introduced into ES cells, and those clones surviving G418
selection were screened for homologous recombination. Appropriate
targeting occurred in 3 of the 750 clones screened (Fig.
1B). Pups resulting from
the injection of cells from each clone into blastocysts included a high
percentage of coat color chimeras. Chimeric males were bred to C57BL/6
females to establish hybrid strains carrying a floxed
4
integrin allele (
4flox). Mice heterozygous
and homozygous for the
4flox allele were
observed at the expected ratio, suggesting that introduction of the
neo cassette and loxP sites had not disrupted
4 integrin expression by transcriptional interference. The
4flox/flox mice were phenotypically normal
and fertile, and FACS analysis confirmed that the
4 integrin
expression levels in the BM of
4+/+,
4flox/+, and
4flox/flox littermates were
indistinguishable (Fig.
1C). Deletion of the
4flox allele in these mice was tested for
by using transduction with a retrovirus-expressing Cre recombinase. BM
cells from
4flox/flox mice were transduced
either with a control retrovirus encoding GFP (MSCViresGFP) or
one in which the gene for Cre recombinase was located upstream of an
internal ribosomal entry site (MSCV-cre-iresGFP). FACS
analysis showed that only GFP+ cells transduced by
MSCV-cre-iresGFP were
4 integrin deficient (data not
shown). The resulting populations of transduced cells were sorted and
plated in methylcellulose, and colonies were then analyzed a week later
by Southern blotting. This analysis confirmed that the loss of
4 integrin expression after MSCV-cre-iresGFP
transduction resulted from total excision between the loxP
sites flanking the proximal end of the
4 gene to give
a deleted allele (
4
) of the
appropriate size (Fig.
1B).
|
4 integrin
deletion.
To produce an
inducible
4 integrin knockout, our
4flox/flox mice were bred to
Mx.cre transgenic animals, in which the interferon-inducible
Mx promoter regulates Cre recombinase expression
(27). To induce Cre
expression, adult
Mx.cre+
4+/+
and
Mx.cre+
4flox/flox
mice were injected three times with poly(I)poly(C), a synthetic RNA
molecule that stimulates endogenous interferon expression; the mice
were euthanized 2 weeks after the last injection. In an analysis of 31
mice of each genotype, only 3.7% ± 0.2% of BM
cells isolated from the
4
/
mice expressed
4 integrin, compared to 93.0% ± 0.9% in
4+/+ mice (P
< 0.001), as illustrated by the typical FACS profiles shown in
Fig.
2A. Concurrent FACS analysis of the
2,
5,
6, and
ß2 integrins revealed that their expression patterns in BM
cells did not alter (data not shown). However, deletion of the
4 gene reduced the levels of ß1 integrin
expressed in BM cells, as indicated by reduced intensity of
fluorescence after antibody staining and a marked decrease in frequency
of cells expressing high levels of ß1 (Fig.
2A).Polymerase chain reaction and FACS analysis of 25 randomly selected
individual colonies derived from the BM CFU-C subset of
4
/
mice confirmed that
these had undergone deletion of the gene in vivo and were
4
integrin deficient (data not shown).
|
4 integrin-deficient BM 2 weeks after deletion was
examined through the expression of lineage-affiliated cell surface
markers. No differences in the number of myeloid
(Mac1+) or erythroid (Ter119+)
cells in the BM were noted (n = 16 per genotype).
However, small but significant reductions in the proportion of the
B220+ B cells (24.9% ± 1.1% in
4+/+ versus 20.8% ±
1.0% in
4
/
; n
= 16; P < 0.01) and CD4+
T-cell populations (1.7% ± 0.1% in
4+/+ versus 1.0% ±
0.05% in
4
/
; n
= 16; P < 0.0002) were noted. Differential
analysis of PB 2 weeks after poly(I)poly(C) treatment
showed significantly increased (P < 0.001) white blood
cell counts in the mice with induced deletion of
4 ([12.8 ± 0.5]
x 106 per ml compared to [7.5 ±
0.3] x 106 per ml in control mice; n
= 45 per genotype). This leukocytosis was due primarily to
increased numbers of circulating lymphocytes and persisted for at least
50 weeks after induced deletion. Red blood cell and platelet numbers,
however, were unaffected by
deletion.
Progenitor distribution in the
absence of
4 integrin.
Assays of clonogenic progenitors
performed using BM cells from 16
Mx.cre+
4+/+
and 16
Mx.cre+
4
/
mice showed that hematopoietic progenitor numbers (total CFU-C) were
not affected 2 weeks after deletion (52,488 ± 7,543 per femur
in
4+/+ mice; 49,554
± 3,615 per femur in
4
/
mice [Fig.
2B]). Circulating
levels of progenitors in the blood of 45
Mx.cre+
4+/+and 45
Mx.cre+
4
/
mice were also evaluated 2 weeks after poly(I)poly(C) treatment. A
dramatic increase in circulating progenitor cell numbers was noted in
the absence of
4 integrin, from 142 ± 13 CFU-C per ml
in control mice to 1,177 ± 71 CFU-C per ml in mice with induced
deletion (P < 0.001). In addition to their increase in
the PB, the number of progenitor cells within the spleen also increased
following deletion, from 29,538 ± 2,549 in controls to 39,994
± 3,680 per spleen in deletion-induced mice(n = 10 per genotype; P <
0.05).
The above data suggested that the distribution of
progenitor cells is altered soon after
4 integrin deletion,
most likely as a result of their ongoing release from the BM. To pursue
these changes further and to characterize the kinetics of circulating
CFU-C, we followed progenitor cell number and distribution in four
additional
Mx.cre+
4+/+
and
Mx.cre+
4
/
mice over time. We found that circulating CFU-C levels remained
elevated for the entire 28-week observation period, although their
frequency gradually decreased before stabilizing (Fig.
3A). The spleens of these deletion-induced mice showed a progressive
increase in progenitor content over time, from the 39,994 ±
3,680 CFU-C per spleen observed 2 weeks after deletion (Fig.
2B) to 79,096 ±
14,428 CFU-C 28 weeks after deletion (Fig.
3A) (P <
0.05). In contrast, the levels of circulating CFU-C and splenic CFU-C
did not change in control animals (Fig.
2B and
3A). The calculated
combined progenitor content of the PB, total BM (see Materials and
Methods), and spleen had increased by 50% as a consequence of
4 integrin deletion, from 916,566 ± 19,742 CFU-C in
the
4+/+ mice to 1,364,325
± 68,312 in the
4
/
mice (P
< 0.005). FACS analysis of BM cells and CFU-C-derived cells
from these
Mx.cre+
4
/
mice revealed no reemergence of
4 integrin-expressing cells in
the 28 weeks following deletion.
|
4
/
mice was appreciably higher than that in a cohort of nonsplenectomized
Mx.cre+
4
/
animals (P < 0.05), supporting the notion that the
spleen continuously sequesters many circulating
4
integrin-deficient progenitors (Fig.
3B). The PB progenitor
cell frequency in splenectomized deletion-induced mice also decreased
over time, albeit at a much lower rate than that observed in
nonsplenectomized deletion-induced animals. Furthermore, 50 weeks after
deletion was induced, the progenitor content of the BM of
splenectomized
4
/
mice
was significantly less (P < 0.01) than that of
splenectomized
4+/+ mice
(38,159 ± 2,246 CFU-C per femur [n =
4] and 50,965 ± 733 CFU-C per femur [n
= 4], respectively [Fig.
3C]). This was in
direct contrast to the BM of nonsplenectomized
4
/
animals analyzed 50
weeks after deletion, in which progenitor numbers had increased
compared to
4+/+ mice
(83,078 ± 8,652 CFU-C per femur [n =
4] and 52,285 ± 3,336 CFU-C per femur [n
= 4], respectively; P < 0.05).
Preliminary evaluation of cycling cells of
4-deleted
BM in the presence or absence of the spleen showed no statistically
significant differences. (Percentage of cycling cells in BM of
4+/+ splenectomized
animals was 24.2% ± 3.59%, whereas it was
29.7% ± 2.0% in
4-/- splenectomized and
34.1 ± 2.4% in
4-/- nonsplenectomized
mice [n = 4 per group].) Whether the rate of
apoptosis is different in the BM of splenectomized animals was not
explored.
4 integrin is required
for efficient recovery from hemolytic anemia.
Because of the impact of
4
integrins during erythropoiesis shown previously
(3,
15), we tested the
responses of recently deletion-induced animals to anemia by inducing
acute hemolysis with PHZ, a scenario in which recovery depends on the
erythroid progenitor reserve. Induction of anemia produced a drop in
hematocrit from 50.8% ± 0.7% to 22.3%
± 1.8% in Mx.cre+
4+/+ mice and from
50.3% ± 1.0% to 23.4% ±
1.3% in
Mx.cre+
4
/
mice 2 days after the second of two daily PHZ injections (n
= 6 per genotype). At this time, reticulocytes were
29.3% ± 2.3% of the
4+/+ PB and 18.5%
± 1.9% in
4
/
PB (P
< 0.05), suggesting an impaired generation of reticulocytes in
4 integrin-deficient mice (Fig.
4A). Consistent with this hypothesis, red blood cell levels were lower in
4
/
mice throughout the
period of recovery examined (P < 0.05 6 days after
PHZ; P < 0.01 10 days after PHZ). Also, PHZ exposure
induced a rapid, transient thrombocytosis in control mice similar in
nature to that previously reported
(12), but thrombocytosis
was not observed in animals in which the
4 integrin had been
deleted. The mechanisms involved in platelet release from
megakaryocytes residing in the BM or spleen after the induction of
anemia are currently unclear; absence of rebound thrombocytosis in
4 integrin-deficient animals, however, suggests a role for
4 integrin in this process.
|
4 integrin,
five additional
Mx.cre+
4+/+and
Mx.cre+
4
/
animals were also analyzed 2 days after the last PHZ treatment. FACS
analysis of
4
/
BM cells
showed that Ter119+ cell numbers were reduced to
(7.6 ± 0.4) x 106 per femur compared with
(11.2 ± 0.7) x 106 in control mice
(P < 0.005). Concomitantly, CFU-e and especially BFU-e
numbers were reduced in the
4
/
BM compared to
control BM (P < 0.1 and 0.05, respectively) (Fig.
4B). BFU-e numbers were
also reduced in the spleens of deletion-induced mice, from 125,363
± 25,528 in control spleens to 46,902 ± 17,915
(P < 0.05). In the PB, an 11-fold difference in CFU-e
number was observed in
4 integrin-deleted animals (83
± 29 per ml in
4+/+ mice versus 964
± 296 per ml in
4
/
mice; P
< 0.05). In contrast, PB BFU-e levels did not change (855
± 191 per ml in
4+/+ mice and 1,213
± 383 per ml in
4
/
mice; P
> 0.1). The number of
4
/
megakaryocytic
progenitors did not differ from controls in any of the tissues examined
(data not shown). The combined number of BFU-e in the PB, BM, and
spleen of deletion-induced mice was significantly less than that of
control mice ([0.8 ± 0.2] x 105
and [2.9 ± 0.6] x 105 BFU-e,
respectively; P < 0.05), and this reduced number was
likely responsible for the observed delayed recovery from anemia in
4 integrin-deleted mice. Interestingly, this delay in
progenitor recovery occurred despite their greater number prior to PHZ
treatment and did not impair their preferential release into the blood
during recovery.
Response of
4
integrin-deficient BM cells to hematopoietic stress by 5FU.
Exposure to 5FU selectively kills
cycling hematopoietic cells
(30,
60), with recovery
involving the recruitment of quiescent stem and progenitor cells into
the cell cycle (51). To
test the ability of myeloid progenitor cells to recover from
hematopoietic stress in the absence of
4 integrin, we treated
four groups of five
Mx.cre+
4+/+
and five
Mx.cre+
4
/
mice with 5FU and then assayed the PB and BM cell and progenitor
content during the recovery phase 4, 8, 12, and 16 days later. BM
cellularity was severely affected by the fourth day in both groups of
mice; progenitor numbers were reduced to 670 ± 136 CFU-C per
4+/+ femur and to 1,371
± 699 CFU-C per
4
/
femur (Fig.
5). By day 8, BM cellularity had doubled in control mice, whereas it was
unchanged in deletion-induced mice (P > 0.1). At this
time, CFU-C numbers were 23,390 ± 6,144 per
4
/
femur compared to
37,815 ± 10,393 per
4+/+ femur. Thus, between
days 4 and 8, the progenitor content of the
4+/+ BM increased by an
average of 56-fold, compared to 17-fold in
4
/
mice (P
< 0.05). By day 12, progenitor numbers had recovered to
near-normal levels in the BM of both groups of mice.
|
4
/
BM cells between days
4 and 8, white blood cell numbers in the PB of deletion-induced animals
dropped lower than those of controls (P < 0.1),
reaching a nadir of 12.7% ± 14.4% of
4
/
steady-state levels
compared with 40.5% ± 18.6% in controls (Fig.
5). By day 16, leukocyte
numbers in the deletion-induced mice increased to two-thirds of their
steady-state level, whereas levels in
4+/+ mice had completely
recovered. Similarly, the kinetics of progenitor cell release into the
PB is delayed in the absence of
4 integrin expression. PB
analysis 8 days after 5FU exposure showed that the number of
circulating progenitor cells in controls increased to four times the
normal level (390 ± 161 CFU-C per ml compared to 101 ±
2 CFU-C per ml). However, at the same time, progenitor numbers in
deletion-induced mice were lower than their baseline levels (101
± 4 CFU-C per ml compared to 1,030 ± 90 CFU-C per ml;
P < 0.001). PB progenitor numbers in both groups of
mice peaked on day 12, when BM recovery was nearing completion (3,414
± 696 CFU-C per ml in controls compared to 10,958 ±
4,286 CFU-C per ml in deletion-induced mice; P <
0.05). The latter data are consistent with an enhanced mobilization of
progenitor cells observed in primates during the early post-5FU
recovery period by concurrent administration of function blocking
4 integrin antibodies(9).
4
integrin-null cells have reduced BM homing and short-term
engraftment.
To examine the
ability of
4 integrin-deleted adult hematopoietic cells to
home, we studied homing to hematopoietic tissues after injection of BM
cells from
Mx.cre+
4+/+or Mx.cre+
4
/
donor mice into
lethally irradiated recipient mice (n = 5 recipients
per donor BM genotype). To assess homing, the number of donor
clonogenic progenitors (CFU-C) recovered in PB, BM, and spleen
24 h after their intravenous injection was estimated as a
fraction of the total number of CFU-C injected. Previous experiments
have indicated that BM homing levels are not significantly different
from 3 to 24 h after injection and that they are largely
unaffected as yet by proliferation
(57). Total BM progenitor
homing (calculated from the femur data, as described in Materials and
Methods) was estimated at 14.1% ± 0.8% of
injected
4+/+ CFU-C but
only at 9.3% ± 0.9% of injected
4
/
CFU-C (P
< 0.005) (Fig.
6A). Concurrently, fourfold-higher numbers of progenitor cells remained
circulating in the PB in the absence of
4 integrin (P
< 0.001). Increased CFU-C accumulation was observed in the
spleens of these recipients, with 13.2% ± 0.9% of
injected CFU-C recovered from animals receiving deletion-induced BM
cells compared to 8.7% ± 0.5% of injected CFU-C
using control BM (P < 0.005). These data confirm the
selective inhibition of BM homing observed earlier using function
blocking antibodies
(42).
|
4
integrin-deficient cells, the participation of additional molecules in
this process was suggested. We previously identified a synergistic
contribution by ß2 integrins in homing by using blocking
antibodies to both
4 and ß2 integrin or using
CD18-deficient donor BM cells treated with anti-
4 integrin
antibody (45). To test
the behavior of our
4 integrin-deleted cells, we treated BM
cells from
Mx.cre+
4+/+
and
Mx.cre+
4
/
animals with anti-leukocyte function-associated antigen 1
(LFA-1) antibody prior to injection. Marrow homing in
irradiated recipient mice (n = 5 recipients per donor
BM sample) was dramatically impaired in the combined absence of
4 and ß2 integrin function, as only 1.1%
± 0.1% of treated
4
/
CFU-C were recovered
from the total BM compared to 9.7% ± 0.8% of the
injected
4+/+ CFU-C
(P < 0.001) (Fig.
6B). Again, higher CFU-C
numbers were observed in the spleens of
4
/
recipient mice
(20.6% ± 0.7% of injected
4
/
CFU-C compared to
4.3% ± 0.6% of injected
4+/+ CFU-C; P
< 0.001), and in the PB (0.214% ± 0.027%
and 0.015% ± 0.003%, respectively; P
< 0.005).
In addition to homing, we studied the kinetics
of early BM repopulation by homed
4 integrin-expressing and
4 integrin-deficient progenitors. Normal
4+/+ recipient animals
were irradiated and each infused with 0.5 x 106
cells from
Mx.cre+
4+/+or
Mx.cre+
4
/
BM (n = 5 recipient mice per donor BM genotype). All
mice were alive 12 days later, at which point they were sacrificed for
analysis. The recipients of
4
/
cells had reduced BM
cellularity ([1.9 ± 0.2] x 106
cells per femur compared to [3.7 ± 0.3] x
106 cells per femur in recipients of control cells;
P < 0.005). Moreover, a fivefold difference in the BM
progenitor content of these animals was observed, with the recipients
of
4+/+ cells having 264
± 99 CFU-C per femur and recipients of
4
/
cells having only 49
± 5 CFU-C per femur (P < 0.05) (Fig.
7A). The total CFU-C content of the spleen was unaffected, averaging 12,245
± 1,629 CFU-C in the five recipients of control BM and 11,856
± 1,754 CFU-C in the five recipients of
4
/
BM (P
> 0.1). Furthermore, comparable numbers of donor-derived
macroscopically visible colonies in the spleen were observed in both
groups of recipient mice, demonstrating normal CFU-S12
development within the spleen in the absence of
4
integrin.
|
4 integrin-deficient cells), and
sacrificed 12 days after transplant for analysis. At that time,
recipients of 106
4+/+ BM cells generated
12,166 ± 6,146 CFU-C per femur, whereas recipients of
4
/
cells had only 697
± 431 CFU-C per femur. Even when a dose of 5 x
106 deletion-induced cells was used, progenitor numbers
recovered from the BM were lower than those in recipients of
106 non-deletion-induced cells (7,889 ± 2,625 CFU-C
per femur in controls compared to 12,166 ± 6,146 CFU-C per
femur in recipients of deletion-induced cells). Interestingly, there
was a significant reduction of circulating
4-deficient
progenitors in splenectomized versus nonsplenectomized recipients,
reflecting the drastic decrease in total progenitor content in these
mice (Fig. 7B). The data
in aggregate confirm results with nonsplenectomized animals and
strongly support the argument that
4 integrin-deficient cells
have a profound impairment in BM-dependent progenitor cell expansion
shortly after transplantation over and above the expected levels from
the partial BM homing
deficit. | DISCUSSION |
|---|
|
|
|---|
4
integrins.
Deletion of the
4 integrin gene resulted in an efflux of deletion-induced
hematopoietic progenitor cells from the BM into the circulation, which
continued for as long as the mice were tested (more than 50
weeks). As the circulating pool of progenitors accounts for
only a small proportion of the total BM progenitor population and is
likely to have a short turnover time
(67), static quantitative
measurements of the
4 integrin-deficient progenitor cells in
the PB likely underestimate the true number of progenitors leaving the
BM compartment as a result of deletion. Although the kinetics of
circulating progenitors may also be perturbed in
4
integrin-deleted animals, our analyses suggest that their homing to
tissues other than the BM is not expected to be
perturbed.
Sustained egress of progenitors into the circulation
for over 12 months strongly suggested that
4 integrin was
deleted in primitive multipotential progenitor cells responsible for
the generation of all those progenitors found in the circulation and
that no compensatory mechanism(s) had emerged to correct this
phenotype. Nevertheless, a decrease in circulating progenitor numbers
was seen over time before a plateau was eventually established. What
caused this downward trend? The following possibilities were
entertained: (i) that a stem cell escaping
4 integrin deletion
slowly expanded to generate descendants that express
4
integrin and consequently remained within the BM or (ii)
that the spleen avidly siphoned off many of the circulating progenitor
cells. Studies of
4 integrin expression levels in total BM
cells, as well as in CFU-C-derived cells, provided no evidence of an
increasing contribution by stem or progenitor cells with nondeleted
4 integrin over time. The role of the spleen in the reduction
of circulating progenitor cells was studied in parallel in a cohort
consisting of splenectomized and nonsplenectomized animals. In
nonsplenectomized
4
/
animals, there was an increase in progenitor numbers within the spleen,
suggesting that the spleen increasingly takes up many of these cells,
although their subsequent expansion within the spleen remains a
possibility. The presence of increased numbers of circulating
progenitors in splenectomized
4 integrin-deficient mice
compared to matched nonsplenectomized animals is not only consistent
with the above interpretation but also suggests that the circulating
progenitor cells originate in the marrow. Nevertheless, a gradual
decrease in their numbers in the PB was also documented in
splenectomized
Mx.cre+
4
/
animals over time, suggesting that factors in these mice in addition to
splenic uptake contribute to the observed decline. Studies of the BM
from splenectomized and nonsplenectomized animals were informative. The
progenitor content 28 weeks after deletion was significantly higher in
nonsplenectomized Mx.cre+
4
/
mice than in normal
controls and splenectomized
Mx.cre+
4
/
animals. Although increased progenitor proliferation in the absence of
4 integrin could be implicated in the increase in BM
progenitors on the basis of prior in vitro data
(33,
53,
73), we found no
statistically significant differences in the in vivo cell cycling in
the BM of these mice. Other possibilities considered were a decrease in
apoptosis of
4-deleted cells, which was unlikely, and a
limited continuous reentry of circulating progenitors into the BM,
especially under conditions of enhanced mobilization (according to a
recent study
[1]). Although
the latter hypothesis will be prospectively tested using parabiotic
pairs, it should have also occurred in splenectomized mice. Since this
was not the case, either a "rehoming" to BM is not
occurring or, if it is, it obscures a dysregulated balance between
proliferation and apoptosis in these mice, as the BM
cellularity was lower in splenectomized animals. Further studies of PB
and BM in splenectomized animals may shed light on this issue. Other
unknown parameters could also be responsible. Furthermore, data
addressing the self-renewal of long-term repopulating cells with
competitive repopulation experiments in serial transplantations are
also needed to resolve some of these
issues.
Progenitor expansion following
stress is impaired in
4 integrin-deficient mice.
Certain aspects of stem or progenitor
cell deficiencies, such as those described for several knockout mice
(i.e., mpl, Tpo, metalloproteinase 9, and placental growth
factor), may be concealed during steady-state hematopoiesis
(8,
11,
16,
17,
24,
64). Perturbation of the
steady state by induction of hematological stress has the potential to
uncover defects that are not normally apparent. Despite the total
increase in hematopoietic progenitors in our mice, a delayed recovery
in regeneration was noted following 5FU treatment. The fact that this
delay was not a consequence of a greater sensitivity of
deletion-induced cells to the killing effects of 5FU (by killing more
cycling cells) was demonstrated when these mice were treated with PHZ,
which causes severe anemia by destroying only mature red cells. As
4 integrin-deficient animals have more progenitor cells than
control mice, the former would have been expected to recover more
rapidly from PHZ-induced anemia. Instead, they exhibited a protracted
recovery, as shown by the kinetics of reticulocyte release into the
circulation. Further assessment revealed a significant impairment in
acute erythroid progenitor cell (BFU-e) expansion in the BM and spleen.
This result is reminiscent of the antiproliferative effects on FL
erythropoiesis observed following administration of an anti-
4
integrin antibody (15).
As erythropoietic recovery from PHZ-induced anemia is critically
dependent upon the increase of kit ligand (KL) and is
drastically impaired in Sl/Sld mice with decreased levels of KL
(7), it can be speculated
that, despite the expected elevated levels of KL in both control and
4 integrin-deleted PHZ-treated mice, a pivotal interaction
between its receptor, c-kit, and
4 integrin was
perturbed in
4 integrin-deleted mice. Our experiments may have
therefore uncovered a previously speculated
(22), but not directly
demonstrated, critical in vivo interaction between
4 integrin
and c-kit that is needed for exponential expansion of
BFU-e.
Homing and short-term engraftment
defects in
4 integrin-deficient cells.
Partial inhibition of homing to the BM
was found when
4 integrin-deleted cells were used in homing
assays. In parallel, increased numbers of circulating donor cells were
detected 24 h after injection along with an increased uptake
by the spleen. This inhibition was comparable to those previously
described by us and which used BM incubated with an anti-
4
integrin antibody as a source of donor cells or which used recipient
mice treated with an anti-VCAM-1 antibody
(42). The ineffectiveness
of anti-
4 integrin antibody treatment in
4
/
mice in comparison to
control animals (Scott et al., unpublished data) provided corroborative
evidence about the specificity of the prior antibody data. The partial
nature of the inhibition, however, suggested that other adhesion
molecules contribute to the homing process. Indeed, we have shown that
treatment of BM cells with anti-ß2 integrin or anti-selectin
antibodies, which do not inhibit homing on their own, provided
synergistic inhibition when used in conjunction with an anti-
4
integrin antibody (45).
Synergism was also observed when ß2 integrin-deficient cells
were treated only with anti-
4 integrin antibody
(45), or as in the
present study, when
4
/
BM cells were incubated with an antibody to LFA-1, one of
the ß2 integrin dimerization partners. LFA-1 is expressed by
progenitors and has been implicated in transendothelial migration of
hematopoietic progenitors in vitro
(74).
In addition
to the homing impairment, an even more pronounced effect on the initial
expansion of
4 integrin-null progenitor cells was observed in
the first 2 weeks after their transplantation. This impairment in
expansion was again restricted to the BM compartment and not to the
spleen. Although some reduction in progenitor number could be
anticipated in the absence of
4 integrin because of their
decreased BM homing ability, the impairment observed was out of
proportion to the homing deficit. This result is highly consistent with
recently published data showing that treatment with anti-
4 and
anti-
5 integrin antibodies inhibits engraftment of cells
delivered directly into the BM microenvironment to bypass any homing
defects (69). We can only
speculate about the molecular basis of these effects. Adhesion of
hematopoietic cells to the BM stroma is thought to maintain the
cells' quiescence rather than stimulate proliferation
(19,
39), and this factor may
be important for their survival in the immediate posttransplantation
period. However, integrins also work in concert with various growth
factors to influence hematopoietic cell proliferation
(32,
54), which is needed at
later stages of recovery following transplantation. This growth
factor-integrin cross talk is particularly strong with receptor
tyrosine kinases, such as c-kit, and the fibroblast and
platelet-derived growth factor receptor family members
(22,
37). Although the levels
of many cytokines and chemokines increase following transplantation or
other conditions of hematopoietic stress
(48,
50), their ability to
protect cell survival and enhance their subsequent proliferation in
these situations was apparently curtailed in our mice following
4 integrin deletion. Further studies with different cell types
will be required to fully uncover the networks operating under such
conditions and to determine whether the balance between proliferation
and survival has been altered in our mice. Nevertheless, it is fair to
suggest that both the effects on homing and on short-term engraftment
observed in recipient mice with normal hemopoietic microenvironment are
consequent to hemopoietic cell-intrinsic defects rather than to
alterations in microenvironment
cells.
Comparison of the
4
integrin-deleted phenotype with that of
4 integrin-null
chimeras and conditional ß1 integrin or VCAM-1
knockouts.
The
data summarized herein revealed several differences from previously
described studies, although there were some similarities. Arroyo et al.
have emphasized a critical role for
4 integrin in normal fetal
erythropoiesis, with knockout animals at the time of death having
smaller, paler livers than those of age-matched controls
(3). Similarly, using
chimeras derived from
4 integrin-null ES cells, these authors
noted impaired terminal erythroid differentiation in the fetus and a
demise in postnatal hematopoiesis contributed by the
4
integrin-null fetal progenitors
(2-4).
As in vitro erythroid differentiation was not affected, these workers
concluded that defective development of
4 integrin-deficient
cells in the FL and postnatal BM resulted from impaired interaction of
4 integrin-deficient (fetal) progenitors with their respective
environments. In agreement with the data of Arroyo et al., we did not
detect any impairment in in vitro erythroid differentiation in the
absence of
4 integrin. However, in contrast to their data with
chimeric mice, our adult
4 integrin-deleted mice did not
display perturbations in steady-state erythropoiesis. As our data
concerned adult cells interacting with an adult BM environment, it is
likely that erythroid progenitor requirements within the adult BM
and/or spleen are distinct from those observed with fetal cells. Such
an explanation was recently suggested to interpret the different
outcomes of stem cell leukemia gene deletion in fetal
versus adult hematopoiesis
(14,
35). Despite the presence
of normal steady-state hematopoiesis, we found that the expansion of
early erythroid progenitors was impaired in the absence of
4
integrin after induced hemolytic anemia. If one interprets the dramatic
expansion of progenitors occurring during fetal development as being
physiologically equivalent to stress, then some similarities with the
previous data can be envisioned. Nevertheless, additional significant
differences between our data and those previously published were
present. Homing and engraftment defects were present in the
4
integrin-deleted mice, although similar defects were not described in
4 integrin-null chimeras. This may be because no formal homing
or transplantation experiments were performed using cells of these
animals. More importantly, the differential requirements for
4
integrin in the adult BM versus the spleen contrast with the profound
hematopoietic impairments observed in both the neonatal BM and the
spleen of the
4 integrin-null chimeric mice
(3,
4). It should be kept in
mind, however, that we induced deletion in adult animals once
hematopoiesis had been well established in these tissues, whereas in
4 integrin-null chimeric mice, integrin-deficient cells failed
to compete with
4+/+ cells
in establishing hematopoiesis.
Drastic homing and migration
deficits have been noted when BM cells from ß1
integrin-conditional knockouts were deleted in vitro and used for
transplantation (49). In
this study, homing to all hematopoietic tissues (BM, thymus, and
spleen) was abolished. Concurrent absence of several
integrins that partner with ß1 integrin may have been
responsible for the extreme inhibition of homing to the BM and the
spleen. Inhibition of homing to the spleen in particular, although
consistent with decade-old data showing inhibition of short-term
(12-day) engraftment in the BM and spleen following treatment with
polyclonal anti-ß1 integrin antibodies
(66), presents a
significant departure from the results we obtained with
4
integrin-deleted BM cells. A disparity in homing to the BM versus to
the spleen has been the rule in several other studies
(29,
42,
59,
65), and the splenic
architecture and its microenvironment, represented by stromal and
endothelial cells, have been suggested as underlying factors in this
difference. However, the extent to which defects are cell intrinsic
rather than dictated by the microenvironment and the nature of
molecular interactions remain to be determined.
Despite the
devastating homing defect in ß1 integrin-deleted cells,
deletion of the ß1 integrin gene in adult animals allowed for
normal hematopoiesis (6).
Brakebusch and coworkers transplanted non-deletion-induced cells into
wild-type recipients and then induced deletion of the floxed ß1
integrin alleles after engraftment was complete in order to overcome
both homing defects and putative defects in nonhematopoietic
microenvironmental recipient cells. It is difficult to compare these
experiments with our transplantation experiments, in which cells were
deprived of
4 before their transplantation in normal
irradiated recipients. Further transplantation experiments using either
normal or
4-deleted animals as recipients may provide
additional insight. However, we believe that the homing and short-term
engraftment defects we observed in normal recipients are likely
attributable to cell-intrinsic defects. Similar experiments have not
been carried out with conditionally deletion-induced ß1 cells
before transplantation. Finally, studies of conditionally
deletion-induced VCAM-1 adult mice uncovered abnormalities in
lymphocyte trafficking, but myeloid cell migration and homing were not
explored (25,
31) for
comparison.
We believe that our
4 integrin-conditional
knockout model will be useful for elucidating molecular interactions
between several classes of hematopoietic cells and their
microenvironment, which are necessary for maintaining hematopoietic
homeostasis and for responding to acute demands as well as for
exploring combinatorial integrin deficiencies or synergistic
interactions with other molecules.
| ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grant numbers HL46557 and HL58734, which were awarded to T.P.
| FOOTNOTES |
|---|